June 23 2022,

TOGETHER WITH

Promotion from Leafwire

If you’re not already on Leafwire, you should be. They’ve grown a TON and have more 10,000 cannabis & hemp job listings on their Job Board.

Create Your Free Account Today

THE BIG IDEA

Happy weekend everyone,

Let’s get to it:

  • Puffco patent suit: A sign of things to come?
  • Pharma’s working on drugs to treat weed addiction

And so, so much more.

Enjoy,

Alex

*

PROMOTION:

For the month of July we’re offering email blasts to our list of ~10,800 subscribers for $999. That’s $500 off the sticker price. Our last three blasts averaged an open rate of 25.42% and 86 unique clicks.

Want an even bigger discount? WeedWeek California Pro subscribers get an additional $250 off.

Contact alex@weedweek.com for more details

*

Follow us on TwitterInstagram and LinkedIn!

*

WeedWeek regularly links to paywalled content

Our advertising policy

WHAT YOU MISSED IN WEEDWEEK CALIFORNIA PRO

puffco
Source: Puffco.com
Dab wars heat up with Puffco patent suit

A patent infringement lawsuit filed by bongmaker Puffco against rival SHO Products looks like a preview of the high stakes intellectual property (IP) litigation awaiting the cannabiz.

A victory for Puffco could frighten off potential competitors for the 20 year life of the patent. But if Puffco loses, lawyers say its patent could be invalidated.  

In its federal suit, Puffco alleges SHO’s Focus V Carta bong infringes on Puffco’s…

Read the story

PLUS: What companies have filed the most cannabis patents?; Can states crack down on Cookies’ Batman merch?

And so much more in the new WeedWeek California Pro.

Pharma researches drugs to treat weed addiction

Tiffany Kary reports in Bloomberg that at least 17 studies are underway in the U.S. for pharmaceuticals to treat cannabis use disorder.

  • One of them, Microdoz Therapy plans to treat cannabis abuse with psychedelic mushrooms and talk therapy. 
  • “I think the coronavirus increased mental health problems in general and addiction in particular,” Pier Vincenzo Piazza, CEO of French company Aelis’, which is developing a treatment for cannabis overuse, said. 
  • The drug isn’t likely to be up for approval until around 2027, he estimates.

Read the whole thing

QUICK HITS

Federal:

Business:

State and local:

Health and science:

Criminal justice:

  • Facing eight years on a psychedelics charge, Denver Rabbi Ben Gorelick plans to plea religious freedom.
    High Times

International:

Fun and interesting:

COMPANY MILESTONES

Courtesy: Alternative Biologics

ON SOCIAL

Was this email forwarded to you?

SIGN UP

View our privacy policy here.